Aurinia Pharmaceuticals Inc. AUPH
Set alert
At close · Oct 30
After hours · Oct 30, 4:03 PM ET
- YTD
- +4.39%
- 1 year
- +37.38%
- Open
- 16.76
- Prev close
- 17.21
- Mkt cap
- 2.22B
- Vol
- 960.84K
- Avg vol
- 925.57K
- EPS
- 2.28
- P/E
- 7.30
- Div yield
- 0.00%
More statistics
- Low
- 16.48
- High
- 17.04
- Forward P/E
- 14.26
- Beta
- 1.61
- Short ratio
- 8.95
- Inst. own
- 60.68%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 25, 2027
- 50-d avg
- 16.50
- 200-d avg
- 15.64
- 1y target
- 18.00
5D chart
Events in this range
- Oct 30, 2026Earnings: 0.23; estimate 0.22; surprise 4.55%
Signals (97)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:05 PM | 2 days ago |
| SMA: Bullish | Oct 30, 11:50 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:40 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:30 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 2:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:45 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 2:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:20 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:10 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:10 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:50 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:20 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:05 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:55 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:45 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:40 AM | 3 days ago |
| RSI: Overbought | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:25 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:15 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:25 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:40 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:25 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:25 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:10 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:35 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:00 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:55 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:25 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:25 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:25 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 5 days ago |
| RSI: Overbought | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:30 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:05 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:05 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:30 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 1:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:25 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 12:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:05 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 11:55 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:45 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:35 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:30 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:10 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
News
2 days ago zacks.com
Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings Estimates
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to earnings of $0.23 per share a year ago.
-
2 days ago benzinga.com
Aurinia Pharmaceuticals Raises FY2026 Sales Guidance from $315.000M-$325.000M to $325.000M-$330.000M vs $330.261M Est
Aurinia Pharmaceuticals (NASDAQ:AUPH) raises FY2026 sales outlook from $315.000 million-$325.000 million to $325.000 million-$330.000 million vs $330.261 million estimate.
-
2 days ago benzinga.com
Aurinia Pharmaceuticals Q3 EPS $0.23 Beats $0.22 Estimate, Sales $83.699M Beat $83.691M Estimate
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.22 by 4.55 percent. This is unchanged from the same period last…
2 days ago businesswire.com
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress
EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2026 and provided an update on…
5 days ago zacks.com
Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
6 days ago zacks.com
Why Aurinia Pharmaceuticals (AUPH) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
1 week ago zacks.com
Why Aurinia Pharmaceuticals (AUPH) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
-
1 week ago benzinga.com
TD Cowen Maintains Buy on Aurinia Pharmaceuticals, Raises Price Target to $18
TD Cowen analyst Stacy Ku maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy and raises the price target from $17 to $18.
2 weeks ago defenseworld.net
Critical Review: Aurinia Pharmaceuticals (NASDAQ:AUPH) versus Madrigal Pharmaceuticals (NASDAQ:MDGL)
Aurinia Pharmaceuticals (NASDAQ: AUPH - Get Free Report) and Madrigal Pharmaceuticals (NASDAQ: MDGL - Get Free Report) are both healthcare companies, but which is the superior investment? We will…
2 months ago zacks.com
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
AUPH settles voclosporin patent litigation with Teva, delaying potential generic competition in the United States until December 2036.
2 months ago benzinga.com
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are up during Thursday's premarket session as the company has entered into a settlement agreement with Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).
2 months ago benzinga.com
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug
Aurinia Pharmaceuticals shares rise after settling patent litigation with Teva, which can launch generic voclosporin no earlier than December 2036.
-
2 months ago benzinga.com
Aurinia Settles Teva Patent Litigation, Protecting Voclosporin Exclusivity In U.S. Until December 2036 And Affirming Validity Of Key Patents Through 2037
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, "Aurinia") have entered into a settlement agreement with Teva…
2 months ago businesswire.com
Aurinia Settles Patent Litigation with Teva
EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Settles Patent Litigation with Teva.
2 months ago seekingalpha.com
Aurinia Pharmaceuticals Doubles Down On Its Pipeline
Aurinia Pharmaceuticals is running the phase 4 PRESERVE trial in lupus nephritis, which tests combinations containing the company's drug Lupkynis. Lupkynis could face potential challenges to its…
-
2 months ago benzinga.com
RBC Capital Maintains Sector Perform on Aurinia Pharmaceuticals, Raises Price Target to $16
RBC Capital analyst Douglas Miehm maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Sector Perform and raises the price target from $15 to $16.
2 months ago zacks.com
Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.16 per share a year ago.
-
2 months ago benzinga.com
Aurinia Pharmaceuticals Affirms FY2026 Sales Guidance of $315.000M-$325.000M vs $323.065M Est
Aurinia Pharmaceuticals (NASDAQ:AUPH) affirms FY2026 sales outlook from $315.000 million-$325.000 million to $315.000 million-$325.000 million vs $323.065 million estimate.
-
2 months ago benzinga.com
Aurinia Pharmaceuticals Q2 EPS $0.28 Beats $0.24 Estimate, Sales $83.220M Beat $79.357M Estimate
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.24 by 16.67 percent. This is a 75 percent increase over earnings…
2 months ago businesswire.com
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress.
3 months ago seekingalpha.com
Playing The Biotech Breakout With Insiders
Biotech stocks are consolidating after a breakout, with bullish insider Wall Street sentiment. AbCellera Biologics and Alpha Cognition stand out for insider buying, revenue growth, and high Seeking…
3 months ago gurufocus.com
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced the initiation of PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNISÂ
3 months ago businesswire.com
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced the initiation of PRESERVE, a Phase 4, multicenter study investigating the combination…
4 months ago zacks.com
Aurinia (AUPH) Upgraded to Strong Buy: Here's Why
Aurinia (AUPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
4 months ago zacks.com
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
4 months ago zacks.com
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
4 months ago zacks.com
Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last?
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in…
4 months ago fool.com
Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million
814,606 common shares acquired for a total transaction value of approximately $12.5 million, based on a weighted average price of $15.29 per share. The purchase represents 6.66% of Kevin Tang's total…
4 months ago benzinga.com
10 Health Care Stocks Whale Activity In Today's Session
10 Health Care Stocks Whale Activity In Today's Session
-
5 months ago benzinga.com
Aurinia Pharmaceuticals' New Analysis Of Aurora 1 Phase 3 Study Of Lupkynis For Lupus Nephritis Shows Statistically Significant 53% Reduction In The Risk Of Renal-related Event Or Death
Hazard ratios (HRs) favored treatment with LUPKYNIS for the following individual components of the composite endpoint: death (HR=0.19 [an 81% reduction in risk]; p=0.0929), treatment failure (HR=0.45…
-
5 months ago benzinga.com
Tang Capital Raises Aurinia Pharmaceuticals Holding to 10%
Tang Capital Management, LLC announces that on June 2, 2026, it acquired 206,005 common shares (the "Common Shares") of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (the "Issuer") at a price of US…
-
5 months ago benzinga.com
Aurinia Pharmaceuticals Affirms FY2026 Sales Guidance of $315.000M-$325.000M vs $326.190M Est
Aurinia Pharmaceuticals (NASDAQ:AUPH) affirms FY2026 sales outlook from $315.000 million-$325.000 million to $315.000 million-$325.000 million vs $326.190 million estimate.
-
5 months ago benzinga.com
Aurinia Pharmaceuticals Q1 EPS $0.25 Beats $0.19 Estimate, Sales $77.705M Beat $77.390M Estimate
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.19 by 31.58 percent. This is a 56.25 percent increase over…
8 months ago benzinga.com
Earnings Scheduled For February 26, 2026
Earnings Scheduled For February 26, 2026
12 months ago benzinga.com
Earnings Scheduled For November 4, 2025
Earnings Scheduled For November 4, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market session. The company's market cap stands at $2.2 million.
-
1 year ago benzinga.com
Earnings Scheduled For February 27, 2025
Earnings Scheduled For February 27, 2025
-
2 years ago benzinga.com
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
-
3 years ago benzinga.com
Earnings Scheduled For November 2, 2023
Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.
-
3 years ago benzinga.com
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
-
3 years ago benzinga.com
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top…
-
3 years ago benzinga.com
Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session.
-
3 years ago benzinga.com
Earnings Scheduled For May 4, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million.
-
3 years ago benzinga.com
Earnings Scheduled For February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 258 companies hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 152 stocks made new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
During Friday's trading, 293 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
OnThursday, 137 stocks made new 52-week lows.